Trial Profile
An open-label, multicentre, randomised, phase III study comparing topotecan/cisplatin and topotecan/etoposide versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive disease-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Topotecan (Primary) ; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors GSK
- 18 Aug 2009 Actual end date (1 Feb 2007) added as reported by ClinicalTrials.gov.
- 26 Jun 2008 Final results reported at ASCO 2008 (1112884)
- 17 Jul 2007 Status changed from in progress to completed.